Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 465
Frequently Asked Questions About the Dual Prevention Pill (DPP)
This factsheet provides answers to the most frequently asked questions about the Dual Prevention Pill (DPP), including what it is, who might use it, and how it can be rolled out.
Prevention Option:
PrEP Initiations by Country Worldwide
AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations around the globe....
Prevention Option:
Tales from Two Cities: HIV and STI research highlights from Brisbane and Chicago
TCA’s invited experts will share their highlights and reflections on the HIV and STI-related science presented at two major global health conferences.
HIV Prevention Research & Development Investments 2021
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, PrEP, treatment as prevention, voluntary medical male circumcision, female condoms and prevention of vertical transmission.
Global Investment in HIV Cure Research & Development in 2021
The 2021 report of Cure Resource Tracking Group, a collaboration between AVAC and the International AIDS Society, showed a remarkable 30 percent increase in funding for cure research. The report also provides an analysis of the cure research agenda and the scientific questions shaping investment decisions.
Prevention Option:
ClusterF*#k: Molecular HIV Surveillance, Criminalization, and The Real Risks to PLHIV
Advocates Brian Minalga (Deputy Director of the Office of HIV/AIDS Network Coordination), Amir Sadeghi (Policy and Advocacy Manager at the The Center for HIV Law and Policy), and Andy Spieldenner (Executive Director of MPact Global Action) will explore the intersection of surveillance, bodily autonomy and criminalization.
A Comprehensive Approach for Progress
Important progress has been made, but ending the AIDS epidemic will require a comprehensive approach that is evidence-informed, rights-based, person-centered and adequately resourced.
Prevention Option:
Phase 1 mRNA HIV Vaccine Trials
A snapshot of early phase trials testing mRNA-based HIV vaccines.
Prevention Option:
PrEP That Booty: The latest on rectal microbicide research for the back door
Most of what we hear about regarding the HIV prevention pipeline is about long-acting, longer-acting, and even longer-acting products that deliver drug throughout the body and require a trained clinician to deliver.
Prevention Option:
Cumulative Number of PrEP Initiations for Q1 of 2023
AVAC tracks PrEP initiations around the world. This infographic represents the cumulative number of PrEP initiations in Q1 2023.
Prevention Option:
showing 1-10 of 465